Achieve Life Sciences (ACHV) announced the submission of a new drug application to the FDA for cytisinicline as a treatment of nicotine dependence for smoking cessation in adults.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHV:
- Achieve Life Sciences Elects Board at Annual Meeting
- Achieve Life Sciences to present new data at 2025 ATS International Conference
- Achieve Life Sciences’ Optimistic Earnings Call Highlights
- Optimistic Buy Rating for Achieve Life Sciences Driven by Cytisinicline’s Regulatory Progress and Strategic Focus on Smoking and Vaping Cessation
- Achieve Life Sciences Reports Q1 2025 Results